FDA Grants Modified Risk Authorization to 22nd Century Group's VLN

FDA Grants Modified Risk Authorization to 22nd Century Group’s VLN

22nd Century Group, Inc., a leading agricultural biotechnology company that is focused on tobacco harm reduction and reduced nicotine tobacco products, has announced that...
IQOS | Altria Group and Philip Morris USA

FDA Authorizes IQOS to be Marketed as Modified Risk Tobacco Product

The U.S. Food and Drug Administration (FDA) has given Altria Group the ok to market its heat not burn device, IQOS, as a modified...
PMI iQOS FDA Harm Reduction

Is the FDA on the Brink of True Harm Reduction?

In July, the FDA announced a new regulatory plan to focus on reducing nicotine levels in cigarettes, with the purpose of reducing cigarette addiction....
British American Tobacco Releases 2018 Harm Reduction Focus Report

British American Tobacco Releases 2018 Harm Reduction Focus Report

Harm reduction has been a major initiative and focus of British American Tobacco (BAT) in recent years and 2018 was no different. With the...
Philip Morris International's Revenue and Stock Jumps Due to IQOS

Philip Morris International’s Revenue and Stock Jumps Due to IQOS

Philip Morris International (PMI) can thank the emerging market of heat-not-burn for not only meeting but beating recent revenue estimates. Earlier this year, the U.S....
FDA Authorizes Philip Morris USA to Sell IQOS in U.S.

FDA Authorizes Philip Morris USA to Sell IQOS in U.S.

Altria Group, Inc. has revealed that it has received authorization from the U.S. Food and Drug Administration (FDA) to sell its heat-not-burn device, IQOS,...
- Advertisement -